Digital cell morphology market seen reaching $3.49 billion by 2030

The digital cell morphology system market is projected to grow from $2.1 billion in 2025 to $3.49 billion by 2030, driven by demand for more precise blood cell analysis, automation, and AI-enabled diagnostics. North America led the market in 2025, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - Digital cell morphology systems are becoming more important as labs and hospitals look for faster, more consistent blood cell analysis. - The market’s projected rise to $3.49 billion by 2030 signals expanding demand for automated diagnostic tools in hematology and related research. - Growing use of remote lab services and telemedicine could make digital morphology more useful outside traditional lab settings.

What happened: - The Business Research Company said the digital cell morphology system market will grow from $2.1 billion in 2025 to $2.33 billion in 2026. - The report projects the market will reach $3.49 billion by 2030, implying a 10.6% CAGR for the forecast period. - The report was published as The Business Research Company’s Digital Cell Morphology System Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035. - The company also made a free sample report available through its website: Download a free sample of the digital cell morphology system market report.

The details: - A digital cell morphology system captures, analyzes and archives high-resolution images of cells in blood and bodily fluids. - The systems automate work that was traditionally done through manual microscopic review. - The technology is designed to improve diagnostic accuracy, streamline lab workflows, ensure consistency and support early detection of hematological conditions. - The market’s recent growth has been supported by reliance on manual microscopic methods, demand for precise hematology diagnostics, limited penetration of digital imaging, expansion of research and academic institutions and a rising prevalence of blood-related disorders. - Future growth drivers include better image-processing software, wider adoption of flow cytometry and automated analyzers, higher biotech and pharmaceutical research spending, AI-powered diagnostic tools and telemedicine. - Key trends include automated cell imaging and analysis, broader use of high-content screening in hematology and oncology, improved lab efficiency and standardization, growth in consumables and reagents, and telepathology and remote diagnostic solutions. - In 2025, North America held the largest share of the market. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The regional analysis also covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - The report’s 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, and updated graphics and tables.

Between the lines: - The forecast points to a market moving from manual review toward software-driven diagnostics. - The emphasis on AI, automation and remote services suggests digital morphology is becoming part of a broader shift in laboratory modernization. - The regional split suggests mature adoption in North America and faster catch-up growth in Asia-Pacific. - The report cites the World Federation of Hemophilia’s Annual Global Survey 2024, which showed a 6% increase in diagnosed hemophilia cases worldwide, a 6% rise in von Willebrand disease recognitions and a 9% increase in other inherited bleeding disorders. - The same survey reported a 9% rise in women and girls diagnosed with bleeding conditions, reinforcing the need for more advanced diagnostics.

What's next: - The market is expected to keep expanding as labs adopt more automated analyzers, AI tools and remote diagnostic workflows. - Asia-Pacific’s growth rate could reshape regional market share if adoption accelerates as projected. - The report positions digital cell morphology as a beneficiary of broader investment in biotech, pharma research and hematology diagnostics.

The bottom line: - Digital cell morphology is shifting from a niche lab tool to a larger diagnostics category with strong growth potential through 2030.